Tutorials
OCSE:ZEAL (Denmark)  
Zealand Pharma A/S logo

Zealand Pharma A/S

kr 132.20 (+7.92%) Aug 11
P/E:
At Loss
P/B:
8.05
Market Cap:
kr 5.71B ($ 791.76M)
Enterprise V:
kr 5.38B ($ 745.61M)
Volume:
259.55K
Avg Vol (2M):
146.87K
Also Trade In:
Volume:
259.55K
Market Cap kr:
5.71B
Market Cap $:
791.76M
PE Ratio:
At Loss
Avg Vol (2-Month):
146.87K
Enterprise Value kr:
5.38B
Enterprise Value $:
745.61M
PB Ratio:
8.05
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website Sources Stock Report
Dataset
Financial Download Tutorials

Business Description

Description
Zealand Pharma A/S is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. Its products include soliqua 100/33/suliqua and adlyxin. The firm focuses on gastrointestinal diseases and metabolic diseases. Its product pipeline includes dasiglucagon, glepaglutide, and dual glucagon product candidates.
Name Current Vs Industry Vs History
Cash-To-Debt 1.42
Equity-to-Asset 0.39
Debt-to-Equity 1.11
Debt-to-EBITDA -0.85
Piotroski F-Score 1/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -0.59
Distress
Grey
Safe
Beneish M-Score -2.72
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 65.55
9-Day RSI 64.14
14-Day RSI 65.37
6-1 Month Momentum % -7.78
12-1 Month Momentum % -40.39

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 4.79
Quick Ratio 4.78
Cash Ratio 3.4
Days Inventory 327.5
Days Sales Outstanding 108.52
Days Payable 212.17

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -12

Financials (Next Earnings Date:2022-11-10)

OCSE:ZEAL's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil kr) 259.825
EPS (TTM) (kr) -23.13
Beta 1.32
Volatility % 71.29
14-Day RSI 65.37
14-Day ATR (kr) 5.544452
20-Day SMA (kr) 126.31
12-1 Month Momentum % -40.39
52-Week Range (kr) 69.55 - 213
Shares Outstanding (Mil) 43.22

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 1
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Zealand Pharma A/S Filings

Document Form Filing Date
No Filing Data